%0 Journal Article
%T A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children.
%A Yuan JJ
%A Wu 
%A Wang WW
%A Duan J
%A Xu XY
%A Tang JL
%J Zhongguo Dang Dai Er Ke Za Zhi
%V 23
%N 8
%D Aug 2021 15
%M 34511166
暂无%R 10.7499/j.issn.1008-8830.2106042
%X <B>OBJECTIVE: </B>To study the clinical effect of mouse nerve growth factor (mNGF) in the treatment of children with global developmental delay (GDD).<BR><B>METHODS: </B>A prospective clinical trial was conducted in 60 children with GDD who were treated in the First Affiliated Hospital of Anhui Medical University between July 2016 and July 2017. These children were randomly divided into two groups: conventional rehabilitation treatment and mNGF treatment group (n=30 each). The children in the conventional rehabilitation treatment group were given neurodevelopmental therapy, and those in the mNGF treatment group were given mNGF treatment in addition to the treatment in the control group. The evaluation results of the Gesell Developmental Scale were compared between the two groups before and after treatment.<BR><B>RESULTS: </B>Before treatment and after 1.5 months of treatment, there was no significant difference in the developmental quotient (DQ) of each functional area of the Gesell Developmental Scale between the mNGF treatment and conventional rehabilitation treatment groups (P>0.05). After 3 months of treatment, the mNGF treatment group had significantly higher DQs of gross motor, fine motor, and personal-social interaction than the conventional rehabilitation treatment group (P˂0.05). The incidence rate of transient injection site pain after injection of mNGF was 7% (2/30), and there was no epilepsy or other serious adverse reactions.<BR><B>CONCLUSIONS: </B>In children with GDD, routine rehabilitation training combined with mNGF therapy can significantly improve their cognitive, motor, and social abilities.<BR>目的: 观察鼠神经生长因子（mouse nerve growth factor，mNGF）治疗儿童全面性发育迟缓的临床疗效。方法: 前瞻性选取安徽医科大学第一附属医院2016年7月至2017年7月收治的60例全面性发育迟缓患儿，随机分为常规康复组与mNGF组，每组各30例。常规康复组采用神经发育学疗法，mNGF组在此基础上，联合mNGF治疗。比较两组患儿在治疗前、治疗中和治疗结束后Gesell发育量表评分的差异。结果: mNGF组和常规康复组治疗前、治疗1.5个月的Gesell发育量表各能区发育商（developmental quotient，DQ）差异无统计学意义（均P>0.05）。治疗3个月后，mNGF组大运动、精细运动和应人能区的DQ高于常规康复组（均P<0.05）。mNGF组一过性注射部位疼痛的发生率为7%（2/30），未发现癫痫等其他严重不良反应。结论: 联合应用mNGF治疗可显著改善全面性发育迟缓患儿的认知、运动和社交能力。.